Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation-Reference-Cited by-同舟云学术

Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation

Published:2019-10-18 Issue:11 Volume:68 Page:1805-1817
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Schwartz Anthony L.^ORCID,Nath Pulak R.^ORCID,Allgauer Michael,Lessey-Morillon Elizabeth C.^ORCID,Sipes John M.,Ridnour Lisa A.^ORCID,Morillon II Y. Maurice,Yu Zhiya,Restifo Nicholas P.^ORCID,Roberts David D.^ORCID

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-019-02397-7.pdf

Reference64 articles.

1. Salomon B, Bluestone JA (2001) Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225–252. https://doi.org/10.1146/annurev.immunol.19.1.225

2. Walunas TL, Bakker CY, Bluestone JA (1996) CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 183:2541–2550

3. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 16:522–530. https://doi.org/10.1016/S1470-2045%5b15%5d70122-1